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Summary Asthma is an inflammatory disease, in which eotaxin, MCP-1 and MCP-3
play a crucial role. These chemokines have been shown to be expressed and produced
by IL-1b-stimulated human airway smooth muscle cells (HASMC) in culture. In the
present study we were interested to unravel the IL-1b-induced signal transduction
leading to chemokine production. Using Western blot, we observed an activation of
p38 MAPK, JNK kinase and p42/p44 ERK when HASMC were stimulated with IL-1b: We
also observed a significant decrease in the expression and the release of eotaxin,
MCP-1 and MCP-3 in the presence of SB203580, an inhibitor of p38 MAPK (7176%,
Po0:05; n ¼ 8 and 39710% Po0:01; n ¼ 10 respectively), curcumin, an inhibitor of
JNK kinase (8374.9% and 8873.4% respectively, Po0:01; n ¼ 4). U0126, an inhibitor
of p42/p44 ERK, also produced a significant decrease in chemokine production
(46.379%, Po0:01 n ¼ 10 and 67.8712%, Po0:01; n ¼ 12)U Pyrrolydine dithiocarba-
mate, an inhibitor of NF-kB was also able to reduce the eotaxin, MCP-1 and MCP-3
expression and production (50713%, Po0:05; n ¼ 10 and 2377%, Po0:05; n ¼ 12).
We conclude that p38 MAPK, JNK kinase, ERK and NF-kB are involved in the IL-1b-
induced eotaxin, MCP-1, and MCP-3 expression and release in HASMC.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Asthma is a chronic inflammatory disease charac-
terised by variable airflow obstruction, bronchial
hyperresponsiveness and airway inflammation.
Mast cells, lymphocytes and eosinophils are the
most important inflammatory cells found in the
airways of untreated asthmatics.1,2 It is now widely
recognised that eosinophils, can cause bronchial
mucosal damage in asthmatic airways, which may
contribute to the symptoms of asthma.3 Eosinophils
are thought to be attracted by a special type of
cytokines, called chemokines. Eotaxin, MCP-1, and
MCP-3 are all members of the C–C chemokine
subgroup. Eotaxin is known to attract eosinophils,
basophils and dendritic cells,4,5 whereas MCP-1 and
MCP-3 also attract other types of inflammatory
cells, such as monocytes and lymphocytes. These
three chemokines can be detected in bronchial
tissue and in bronchoalveolar lavage fluid from
asthmatic subjects,6–8 therefore they might be
important in the pathogenesis of asthma.
IL-1b is a potent proinflammatory cytokine that
has a central role in inflammatory reactions such as
in asthma. IL-1b has been detected in the bronch-
oalveolar lavage fluid from asthmatics but not in
normal subjects and its concentration correlates
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with the severity of asthma.9,10 We have previously
demonstrated that human airway smooth muscle
cells (HASMC) in culture, when stimulated with IL-
1b; can express and release MCP-1, MCP-2 and MCP-
3 mRNA and protein, respectively.11
In the present study, we are interested in the
signalling pathways involved in the IL-1b-induced
chemokine expression and production. So far, three
major subgroups of MAP kinases, involved in IL-1b-
signalling, have been identified: p38 mitogen
activated kinase (p38 MAPK), c-Jun amino-terminal
kinases (JNK kinase), and p42/p44 extracellular
signal-regulated kinases (p42/p44 ERK).12 Several
transcription factors are also activated by IL-1b in
different cell types. NF-kB seems to be the most
important up to now. Binding sites of this transcrip-
tion factor are present in the mouse MCP-1
promoter region.13 Despite numerous reports re-
garding the importance of IL-1b in the cytokine
network, very little is known about the molecular
mechanisms governing eotaxin, MCP-1 and MCP-3
release in HASMC in particular.
As a consequence, the present study is aimed at
unravelling the signal transduction cascade in-
volved in IL-1b-induced chemokine release in
HASMC.
This is the first study to investigate whether the 4
most important constituents of IL-1b-induced signal
transduction are involved in the eotaxin, MCP-1 and
MCP-3 expression and production in HASMC.
Material and methods
Culture of HASMC
HASMC were grown from explants of human
bronchial smooth muscle, as previously de-
scribed.11 Airway tissue was obtained from patients
undergoing surgery for lung carcinoma in accor-
dance with procedures approved by the local
ethical committee. None of the patients had
characteristics of asthma. Bronchial smooth muscle
tissue was isolated by dissection. Small explants
(2 2mm) were prepared and cultured in Dulbec-
co’s Modified Eagle’s Medium (DMEM) supplemented
with 10% foetal bovine calf serum (FBS), L-gluta-
mine (2mM), penicillin (100U/ml), streptomycin
(100 mg/ml) and amphotericin B (1.25 mg/ml).
DMEM was added, just to cover the explants. The
medium was changed every day until the cells
started to grow, then the medium was changed
every 3 days. When the cells reached confluency,
the explants were removed and 24 h later the cells
were harvested with trypsin/EDTA and plated into a
75 cm2 flask. After subculturing the cells twice, the
cultures were characterised immunohistochemi-
cally, using anti-human smooth muscle actin anti-
body. Primary cell cultures used for the
experiments showed 495% of cells staining for
smooth muscle actin. After reaching confluency the
cells were washed and incubated with serum-free
DMEM, for 24 h before stimulation. All experiments
were carried out between passages 3 and 6. The
cells used for these experiments were obtained
from 5–6 different donors.
Experimental protocol
HASMC were stimulated with Il-1b (10 ng/ml) alone
or in combination with several inhibitors for 4 h
(RNA) or 24 h (protein). The mRNA expression and
protein release were compared with those mea-
sured in HASMC stimulated with IL-1b alone. In
some experiments HASMC were stimulated with IL-
1b in the presence of 10 mM SB203580, an inhibitor
of p38 MAP kinase, or 1 mM curcumin, an inhibitor of
JNK kinase, or 10 mM U0126, an inhibitor of p42/p44
ERK, or 10 mM pyrrolydine dithiocarbamate (PDTC),
an inhibitor of NF-kB. HASMC stimulated with IL-1b
alone were used as controls and the results were
expressed as a percentage of the values measured
in cells stimulated with IL-1b alone.
Control cells were stimulated in the presence of
an equivalent amount of vehicle.
Measurement of secreted eotaxin and MCP-1
protein by use of enzyme-linked
immunosorbent assay (ELISA)
MCP-1 and eotaxin proteins were measured in
supernatant of cultured HASMC. This was done
with a commercially available sandwich ELISA kit,
as specified by the manufacturer. These ELISA kits
are highly specific, and there was no significant
interference between any of the cytokines being
investigated. The sensitivity of these assays is high,
with a lower limit of detection of 5.0 pg/ml for
both MCP-1 and eotaxin. The level of MCP-3 protein
was too low to be measured with ELISA.
Northern blot analysis
Total RNA was isolated by phenol/chloroform
extraction and isopropanol precipitation.14 The
RNA samples were subjected to a 1% agarose/
formaldehyde gel, containing 20mM morpholino-
sulfonic acid (MOPS), 5mM sodium acetate and
1mM EDTA (pH 7.0), blotted onto a nylon mem-
brane. Hybridisation was performed with a 227 bp
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fragment specific to the human eotaxin comple-
mentary DNA (cDNA), a 170 bp fragment specific to
the human MCP-1 cDNA, a 700 bp fragment specific
to human MCP-3 cDNA, and a 1200 bp cDNA
fragment specific to rat glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) cDNA. They were
labelled by a random primer labelling kit using
[a-32P]dCTP (3000 Ci/mmol). After prehybridisation
for 4 h at 421C in a buffer containing 50%
formamide, 4 standard sodium citrate (SSC),
50mM Tris-HCl (pH 7.5), 5Denhardt’s solution,
0.1% sodium dodecyl sulphate (SDS), 5mM EDTA and
250 mg/ml denaturated salmon sperm DNA, the
blots were hybridised overnight at 421C with the
labelled probes (1–2 106 cpm/ml). Following hy-
bridisation, the blots were washed to a high
stringency of 0.1 SSC, 0.1% SDS at 551C before
exposure to X-OMAT-S film. After the adequate
exposure time, the autoradiographs were devel-
oped and analysed by a laser densitometer. The
RNA levels were expressed as the ratio of chemo-
kine mRNA to GAPDH mRNA.
Immunoblot analysis of p38 MAP kinase
These were performed as previously described.15
Extraction of cytosolic proteins: following treat-
ment, the cells were rinsed 2 times with cold PBS
and scraped into lysis buffer (25mM HEPES, 0.3M
NaCl, 1.5mM MgCl2 20mM b-glycerolphosphate,
2mM EDTA, 2mM EGTA, 1mM DTT, 1% Triton X-100,
10% glycerol, 10 mg/ml leupeptin, 10 mg/ml aproti-
nin and 1 nM sodium orthovanadate), vortex-mixed
and incubated on ice for 30min. The threonine- and
tyrosine-phoshorylation of p38-MAPK, JNK kinase
and p42/p44 ERK were analysed by Western blot
analysis, using specific polyclonal antibodies. Pro-
tein samples (100 mg, in sample buffer: 62.5mM
Tris, 10% glycerol, 2% SDS and 10mM b-mercap-
toethanol) were separated by SDS-PAGE electro-
phoresis on 14% acrylamide gels and then
transferred to a PVDF-hybond membrane. In order
to block non-specific protein binding, the mem-
brane was incubated at room temperature for 1 h in
TBST blocking buffer (0.1% Tween 20 in Tris-
buffered saline containing 5%w/v skim powdered
milk). The membrane was then incubated overnight
at 41C with either Phospho-p38 MAP kinase poly-
clonal antibodies, JNK kinase or p42/p44 ERK
polyclonal antibodies in TBST without Tween 20.
The membrane was washed 2 times for 5min with
TBST and then incubated with a 1:10 000 dilution of
HRP-conjugated anti-rabbit secondary antibody in
TBST. The membrane was washed 5 times for 15min
each and protein detection was carried out using
enhanced chemiluminescence (ECL) plus detection
reagent and exposed against ECL-Hyperfilm.
Materials and reagents
Cell culture medium (DMEM), fetal bovine serum,
and culture reagents were purchased from Gibco
Life Technologies (Merelbeke, Belgium). The anti-
human smooth muscle actin antibody was obtained
from Dako (Glostrup, Denmark)
Recombinant human IL -1b and ELISA kits for
eotaxin, and MCP-1, were obtained from R&D
Systems Europe Ltd. (Abingdon, UK). SB203580
was purchased from Merck (Leuven, Belgium).
The 227 bp fragment specific to the human
eotaxin complementary DNA (cDNA) was a kind gift
from A. Yokoyama (Ehime, Japan), a 170 bp frag-
ment specific to the human MCP-1 cDNA, and a
700 bp fragment specific to human MCP-3 cDNA,
was a kind gift from G. Opdenakker (Rega institute,
Leuven, Belgium). The 1200 bp cDNA fragment
specific to rat GAPDH cDNA was purchased from
Clontech (Heidelberg, Germany).
Hybridisation was performed with a random
primer labelling kit from MBI Fermentas (St Leon-
Rot, Germany) using [a-32P]dCTP obtained from
Amersham (little Chalfont, UK). The autoradio-
graphs were analysed by a laser densitometer
obtained from Kodak (Rochester, USA).
Phospho-p38 MAPK, JNK kinase polyclonal anti-
bodies were purchased from New England Biolabs,
(Beverly, USA). PVDF-hybond membrane and ECL-
Hyperfilm were obtained from Amersham (little
Chalfont, UK).
All the other used reagents were obtained from
Sigma-Aldrich (Bornem, Belgium).
Statistics
All data are presented as means7SEM. Statistical
analysis was performed using the Mann–Whitney
U-test [Prism 3.0 (GraphPAD) software was used].
Results
Effect of IL-1b on expression and release of
eotaxin, MCP-1 and MCP-3 in HASMC in vitro
Neither mRNA expression nor the protein release of
these chemokines was measurable in unstimulated
HASMC. However, after 24 h of stimulation with IL-
1b, there was an increase in eotaxin and MCP-1
release (1172 and 10779 ng/ml, respectively).
The level of MCP-3 protein was too low to be
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measured with ELISA (data not shown). Eotaxin,
MCP-1, and MCP-3 mRNA expression in HASMC was
clearly present after stimulation with IL-1b (data
not shown).
MAP kinase activation
Immunoblot analysis showed that amounts of
phosphorylated threonine and tyrosine of p38 MAP
kinase in cells stimulated with IL-1b 10ng/ml were
increased at 5min. Peak phosphorylation levels
occurred at 30min and remained significantly
elevated for 1 h after which time the levels
returned to near base line (Fig. 1A).
The amounts of phosphorylated threonine and
tyrosine of JNK kinase in IL-1b-stimulated cells
were significantly increased at 10min. Peak phos-
photyrosine levels occurred at 30min and after 1 h
we observed a complete loss of activation (Fig. 1B).
IL-1b also induced phosphorylation of tyrosine of
p42/p44 ERK with a peak activation at 15min and a
decrease thereafter (Fig. 1C).
Effects of SB203580, curcumin, U0126 and
PDTC on IL-1b-induced release and
expression of eotaxin, MCP-1, and MCP-3 in
HASMC in vitro
Stimulation of the HASMC with SB203580 (10 mM), a
p38 MAPK inhibitor in the presence of IL-1b (10 ng/
ml) for 24 h resulted in a significant reduction of the
eotaxin (7176%, Po0:05; n ¼ 8) and MCP-1
(39710%, Po0:01; n ¼ 10) protein release, com-
pared to IL-1b-stimulated HASMC alone (Fig. 2).
After 4 h of IL-1b stimulation in the presence of
SB203580 (10 mM), the expression of eotaxin, MCP-
1, and MCP-3 mRNA were decreased by 34710%,
2477%, and 4474%, respectively, compared with
IL-1b alone ðn ¼ 4Þ (Fig. 3).
After addition of curcumin (an inhibitor of JNK
kinase), we observed a significant decrease in
eotaxin and MCP-1 production (with a decrease of
8374.9% and 8873.4% with curcumin 1 mM, for
eotaxin and MCP-1, respectively)(Po0:01; n ¼ 4)
(Fig. 2). U0126, an inhibitor of p42/p44 ERK,
produced a significant decrease of eotaxin and
MCP-1 production (57.379% and 57.8712% Po0:01
decrease for eotaxin and MCP-1, respectively for
10mM U0126, n ¼ 10 and 12 respectively)(Fig. 2).
Treatment of the HASMC with PDTC (10 mM), an
NF-kB inhibitor, in the presence of IL-1b, resulted in
a significant decrease of chemokine protein release
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Figure 1 HASMC are stimulated with IL-1b for the time
points indicated. Proteins in cell lysates were separated
by SDS-PAGE prior to immunoblot detection of phos-
phorylated p38 MAP kinase (panel A), JNK (panel B), and
ERK kinase (panel C).
Figure 2 HASMC were treated with IL-1b (10 ng/ml) for
24 h, in the presence or absence of SB203580 (10 mM), an
inhibitor of P38 MAP kinase activity, or U0126 (10 mM), a
selective inhibitor of ERK kinase, or curcumin (1 mM), an
inhibitor of JNK kinase or PDTC (10 mM), an inhibitor of
NF-kB. Cells were pretreated for 30min with these
inhibitors. The effects of these inhibitors are shown, on
eotaxin (panel A) and MCP-1 (panel B) release from cells
stimulated with IL-1b: Data are expressed as a percen-
tage of the control response (IL-1b alone) and are
represented as mean7SEM of duplicate values from
independent experiments using cells cultured from five
different donors, cell passages 3–6. *Po0:05; **Po0:01
compared with stimulated levels in the absence of
inhibitor.
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for eotaxin (50713%, Po0:05; n ¼ 10) and MCP-1
(5077%, Po0:05; n ¼ 12) (Fig. 2). PDTC in combi-
nation with IL-1b also induced a decrease in
eotaxin, MCP-1, and MCP-3 mRNA expression by
6672%, 6272%, and 6778% respectively (n ¼ 4)
(Fig. 3).
Discussion
In the present study we have again confirmed that
HASMC in culture are able to express the chemo-
kines eotaxin, MCP-1 and MCP-3, when stimulated
with the proinflammatory cytokine IL-1b. Likewise,
we have also demonstrated an increase in eotaxin,
and MCP-1 protein release. Using Western blotting,
we observed an activation of p38 MAPK, JNK kinase
and p42/p44 ERK when HASMC were stimulated
with IL-1b: The IL-1b-induced eotaxin, MCP-1 and
MCP-3 release and expression were significantly
decreased by SB203580, an inhibitor of p38 MAPK,
curcumin, an inhibitor of JNK kinase, U0126 an
inhibitor of p42/p44 ERK and PDTC, an inhibitor of
NF-kB. These findings imply an important role for
p38 MAPK, JNK kinase, p42/p44 ERK and NF-kB
in the IL-1b-induced chemokine expression and
release.
In an attempt to identify some key elements that
constitute the link between stimulation with IL-1b
and the expression and production of the above
mentioned chemokines, we evaluated whether p38
MAPK, JNK kinase and p42/p44 ERK, three of the
most important MAP kinases, were activated by IL-
1b in HASMC in vitro. Using Western blotting we
observed an activation of all three elements
studied. Only small numbers of studies examining
the activation of these MAP kinases by IL-1b in
HASMC have been published to date. Our group
already demonstrated that p38 MAP kinase is
activated by IL-1b in HASMC.15 In the present study
we also showed that IL-1b was able to activate JNK
kinase and p42/p44 ERK in HASMC. The involvement
of P38 MAP kinase and p42/44 ERK in eotaxin
has meanwhile been confirmed in an article of
Hallsworth et al.16
Since IL-1b induces a tremendous amount of
different actions, the activation of these three MAP
kinases not directly implies an involvement of all of
them in the IL-1b-induced chemokine expression
and production. Therefore, we stimulated the cells
with IL-1b; in the presence of the specific inhibitors
of these three MAP kinases studied.
Showing that SB203580 was able to reduce the
chemokine expression and production, provides
some more evidence for p38 MAPK being involved
in IL-1b-induced eotaxin, MCP-1 and MCP-3 expres-
sion and production. Recently an article was
published in which it is confirmed that eotaxin
release is dependent on p38 MAP kinase in
HASMC.16 It has been described as well that p38
MAPK is necessary for the IL-1b-induced MCP-1
expression in human mesangial cells,17 but this is,
to our knowledge the first time that the involve-
ment of p38 MAPK in the IL-1b-induced expression
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Figure 3 HASMC were incubated with IL-1b (10 ng/ml) in
the presence or absence of SB203580 (10 mM), an inhibitor
of p38 MAP kinase activity, or PDTC (10 mM), an inhibitor
of NF-kB. Panel A shows the effects of SB 203580 and
PDTC, on eotaxin (panel A), MCP-1 (panel B) and MCP-3
(panel C) expression from cells stimulated with IL-1b
(10 ng/ml) for 4 h. Cells were pretreated for 30min with
pharmacological inhibitors. Data in graphs are derived
from densitometric quantification of autoradiographs
using a laser densitometer and software obtained from
Kodak (Rochester, USA). Data are expressed as a
percentage of the control response to IL-1b alone and
are represented as mean7SEM of duplicate values from
independent experiments using cells cultured from five
different donors, cell passages 3–6.
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and release of MCP-1 and MCP-3 is observed in
HASMC.
We also observed a decrease of the chemokine
production in the presence of curcumin, a specific
inhibitor of JNK kinase,18 which suggest the
involvement of JNK kinase in the IL-1b-induced
signal transduction. In rat and human mesangial
cells, it has already been shown that an activation
of JNK kinase is involved in the MCP-1 produc-
tion.19,20 We did not perform mRNA expression
because in the former experiments mRNA and
protein results were equivalent and because the
protein is the most important product that finally is
responsible for the effects on inflammation.
Nevertheless our paper for the first time demon-
strates that JNK kinase is involved in eotaxin and
MCP-1 production in HASMC.
We also tested U0126, an inhibitor, which is able
to completely block the p42/p44 ERK activity as
demonstrated by a complete inhibition to baseline
levels of its substrate.16 This potent blocker was
able to reduce the IL-1b-induced eotaxin and MCP-1
production. We did not measure the mRNA because
of the same reason mentioned above. As a
consequence, our data also argue in favour of an
involvement of p42/p44 ERK in the IL-1b-induced
release of chemokines.
As NF-kB is also known as an important element
in IL-1b-induced signal transduction, we also
investigated whether NF-kB is involved in the
specific process of expression and release of
chemokines. We have demonstrated, in the present
study, that NF-kB is involved in the IL-1b-induced
release and expression of eotaxin, MCP-1, and MCP-
3 in HASMC. Indeed, PDTC, an inhibitor of NF-kB,21
induced a significant decrease in chemokine protein
release, which was in accordance with our mRNA
findings in HASMC. PDTC has been shown to block
cytokine-induced NF-kB activation in several cell
lines including HASMC.22,23 Our observation that
NF-kB is involved in the IL-1b induced chemokine
release and expression is also consistent with
previous data in other cell types, such as mesangial
cells,24 vascular smooth muscle25 and A549 airway
epithelial cells.26,27
Our results can be of a great importance in the
development of future therapy for inflammatory
diseases of the airways, such as asthma. It has been
shown that the early stages of inflammatory cell
adherence and diapedesis appear to be dependent
upon p38 MAP kinase activation as suggested by the
inhibition of LPS and TNF-a-induced ICAM-1 expres-
sion on pulmonary microvascular endothelial cells
by SB203580.28 It has already been suggested that
the use of a p38 MAP kinase inhibitor may influence
different key processes of chronic inflammation as
seen in asthma.29 Our study provides some more
evidence for this hypothesis and also points to the
possible role of JNK, ERK and NF-kB inhibition in
the treatment of asthma.
Up to now, there is already a lot of information
available about IL-1b-induced signal transduction,
in different cells, however, this is the first study to
investigate the involvement of the 4 most impor-
tant elements in IL-1b-induced eotaxin, MCP-1 and
MCP-3 expression and production in HASMC.
In conclusion we have demonstrated that in
HASMC the IL-1b-induced protein release and mRNA
expression of eotaxin, MCP-1, and MCP-3, in HASMC
is mediated by p38 MAP kinase, JNK kinase, p42/
p44 ERK and NF-kB.
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